Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with ...

This conclusion comes from the phase 3 study EA4151, conducted by the ECOG-ACRIN Cancer Research Group. The trial, which ...

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant ...

The test leverages the company’s immune medicine platform to quantify specific DNA sequences found in malignant cells.

O'Dwyer, MD, Group Co-Chair of ECOG-ACRIN. "The promise of the joint effort is to provide broad availability of cutting-edge options for cancer patients in their communities." As part of the ...

The 66th American Society of Hematology Annual Meeting & Exposition will take place December 7-10, 2024, in San Diego, ...